https://www.selleckchem.com/pr....oducts/semaxanib-su5
7 patient-years. Sixty-seven serious adverse events occurred in 57 patients (20.7%; incidence rate 36.7 per 100 patient-year), and 31 of these events caused the withdrawal of the drug. The effectiveness after 8 weeks of treatment was evaluated in patients naïve to IFX (n = 192) 110 patients (57.3%) had steroid-free remission, while 56 patients had no response (29.2%). At the end of follow-up, 72 patients (26.1%) interrupted the treatment, without significant differences in treatment persistency estimations between the five grou
Like
Comment
Share
